All In Biotech

Free tool

FAERS Monitor: Iopidine

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 020258 or its brand name (Iopidine, Apraclonidine Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

111

Serious

87

78% of reports

Hospitalization

33

Death reported

2

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective21
  • off label use7
  • somnolence7
  • eyelid ptosis6
  • vision blurred6
  • constipation5
  • dry mouth5
  • dyspnoea5
  • eye pain5
  • sinus bradycardia5
  • tenderness5
  • urinary retention5
  • visual acuity reduced5
  • acute kidney injury4
  • angle closure glaucoma4

Reports by year received

View as table
YearReports
20073
20088
20092
20111
20148
20153
20164
20177
201813
20197
202010
20217
20228
20238
202410
20254
20268

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,048 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
angle closure glaucomaSignal4297.5113.6903
eyelid ptosisSignal6111.951.4553
sinus bradycardiaSignal598.041.6388
tendernessSignal590.938.6359
visual acuity reducedSignal528.512.1107
urinary retentionSignal528.412.1106
eye painSignal516.87.159
dry mouthSignal511.75.039
vision blurredSignal68.33.832
somnolenceSignal76.63.228
acute kidney injurySignal45.01.99
constipationSignal54.31.810
drug ineffectiveSignal213.02.128
dyspnoea51.70.71
off label use71.50.71

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.